Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||NY-ESO-1 recombinant protein|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
|Western Blot (WB)||See 3 publications below|
|Immunohistochemistry (IHC)||See 1 publications below|
|Miscellaneous PubMed (MISC)||See 2 publications below|
|Immunohistochemistry (Paraffin, Frozen) (IHC (P, F))||See 1 publications below|
NY-ESO-1, a member of the CT(cancer/testies) family, is a tumor specific shared antigen with distinctive immunogenicity. The molecular basis of T cell-mediated antitumor immunity has been elucidated by the identification of a number of tumor antigens recognized by CD8+ T cells. Among these antigens, NY-ESO-1 is of particular interest because both the cytotoxic T lymphocyte and antibody have been shown to react with this antigen. The NY-ESO-1 has been detected in normal testis and in a range of human tumor types. NY-ESO-1 reactivity in testis is restricted germ cells, particularly in the spermatogonia.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
35-6200 was used in immunohistochemistry - paraffin section to investigate NY-ESO-1 in mesenchymal tumors
|Endo M,de Graaff MA,Ingram DR,Lim S,Lev DC,Briaire-de Bruijn IH,Somaiah N,Bovée JV,Lazar AJ,Nielsen TO||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (28:587)||2015|
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.
35-6200 was used in western blot to investigate the effect of SGI-110 on cancer testis antigen gene-regulated expression
|Srivastava P,Paluch BE,Matsuzaki J,James SR,Collamat-Lai G,Karbach J,Nemeth MJ,Taverna P,Karpf AR,Griffiths EA||Leukemia research (38:1332)||2014|
Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
35-6200 was used in western blot to test if demethylating chemotherapy increases the expression of cancer specific antigens.
|Krishnadas DK,Bao L,Bai F,Chencheri SC,Lucas K||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (35:5753)||2014|
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
35-6200 was used in western blot to study mechanisms to pharmacologically increase expression of cancer antigens on neuroblastoma.
|Bao L,Dunham K,Lucas K||Cancer immunology, immunotherapy : CII (60:1299)||2011|
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
35-6200 was used in immunohistochemistry to report enhanced anticancer immunity using dendritic cells to present endocytosed material and initiate T cell immunity.
|Dhodapkar MV,Sznol M,Zhao B,Wang D,Carvajal RD,Keohan ML,Chuang E,Sanborn RE,Lutzky J,Powderly J,Kluger H,Tejwani S,Green J,Ramakrishna V,Crocker A,Vitale L,Yellin M,Davis T,Keler T||Science translational medicine (6:null)||2014|
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
35-6200 was used in flow cytometry to investigate the efficacy of the adoptive cell transfer protocol for melanoma patients.
|Mazzarella T,Cambiaghi V,Rizzo N,Pilla L,Parolini D,Orsenigo E,Colucci A,Modorati G,Doglioni C,Parmiani G,Maccalli C||Cancer immunology, immunotherapy : CII (61:1169)||2012|
γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo.
35-6200 was used in immunohistochemistry (paraffin) to test if γ-radiation increases expression of cancer-testis antigens and MHC-I, thus promotes efficient immunological control.
|Sharma A,Bode B,Wenger RH,Lehmann K,Sartori AA,Moch H,Knuth A,Boehmer Lv,Broek Mv||PloS one (6:null)||2011|
|Human||Not Cited||Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy.||Akcakanat A,Kanda T,Tanabe T,Komukai S,Yajima K,Nakagawa S,Ohashi M,Hatakeyama K||International journal of cancer (118:123)||2006|
autoimmunogenic cancer/testis antigen NY-ESO-1; cancer antigen 3; cancer/testis antigen 6.1; CT6.1; CTAG; CTAG1; CTAG1A; CTAG1B; ESO1; l antigen family member 2; LAGE-2; LAGE2; LAGE2A; LAGE2B; New York esophageal squamous cell carcinoma 1
CT6.1; CTAG; CTAG1; CTAG1A; ESO1; LAGE-2; LAGE2; LAGE2A; LAGE2B; NY-ESO-1